Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) reported on Friday positive high-level results from the global Phase III DUO-E trial showing that Imfinzi (durvalumab), when combined with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with advanced or recurrent endometrial cancer.

This marks the first Phase III trial to demonstrate clinical benefit in this context by combining immunotherapy and PARP inhibition. The combination of Imfinzi and Lynparza as maintenance treatment showed greater clinical benefit.

AstraZeneca noted that although overall survival data were immature during the analysis, a favourable trend was observed for both treatment regimens.

Endometrial cancer is the sixth most common cancer in women globally, and there is a need for novel treatment options.

The safety and tolerability profiles of Imfinzi plus chemotherapy and Imfinzi in combination with Lynparza were consistent with prior trials and known profiles of the medicines.